$2.10
-0.03 (-1.41%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PCSA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 4 with posted results
Held by 2 tracked-famous managers (CITADEL ADVISORS LLC, JANE STREET GROUP, LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · insider 90d: 10 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerNCT06568692Evaluation of Objective Response Rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: PCS6422 and capecitabine, Capecitabine | Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer | 90 | Sep 2026 | ≤ 42 d | 2025-06-19 |
| A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract TumorsNCT04861987Number of participants with dose limiting toxicities (DLT) and incidence of adverse events as assessed by CTCAE v5.0Open-label · Treatment | Phase 1 | Completed | Drug: PCS6422 and capecitabine | Advanced Cancer, Refractory Cancer, Tumor Gastric | 23 | 2024-06-12actual | — | 2024-10-10 |
| A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis LipoidicaNCT04800562Incidence of ulcer closure as assessed by skin exam in patients treated with PCS499 as compared to placeboRandomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: lack of enrollment of this ultra rare disease | Drug: PCS499 · Other: placebo | Necrobiosis Lipoidica | 4 | 2023-02-28actual | — | 2023-08-03 |
| Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe GastroparesisNCT05270460results2023-07-21Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying RateRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PCS12852, Placebo | Gastroparesis | 25 | 2022-09-29actual | — | 2023-07-21 |
| A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis LipoidicaNCT03698864results2022-10-03Evaluation of Patients With Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PCS499 | Necrobiosis Lipoidica | 12 | 2020-02-25actual | — | 2022-10-03 |
| RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic CancerNCT03189914results2023-12-06Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (Phase 1 and 2)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: RX-3117 | Metastatic Pancreatic Cancer | 46 | 2019-10-01actual | — | 2023-12-06 |
| Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced MalignanciesNCT02030067results2023-12-06Overall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: RX-3117 | Solid Tumor, Metastatic Bladder Cancer | 127 | Jul 2019actual | — | 2023-12-06 |
| Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy SubjectsNCT03836222Maximum plasma concentrations (Cmax) for Part 1Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PCS499, Trental | Healthy | 18 | 2018-06-04actual | — | 2019-02-12 |
| Open Label Extension Study of HT-100 in Patients With DMDNCT01978366Safety and tolerability of administration of 6 months of chronic, oral, multiple doses of HT-100 to boys with DMD.Non-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Dosing stopped | Drug: HT-100 | Duchenne Muscular Dystrophy | 17 | 2016-04-30actual | — | 2020-09-03 |
| Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyNCT01847573Safety and tolerability of administering single and multiple ascending doses of HT-100 in DMD boysNon-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Dosing stopped | Drug: HT-100 | Duchenne Muscular Dystrophy | 17 | 2016-03-30actual | — | 2020-09-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19